Regeneron's Eylea still racing ahead; Strong Opsumit launch boosts Actelion forecast; Diabetes texts kept patients on meds;

> Regeneron's ($REGN) Eylea drug continues to grow by leaps and bounds, with $610 million in fourth quarter sales, up from $415 million a year ago. Report

> The Swiss drugmaker Actelion hiked its 2014 earnings forecast after its new treatment for pulmonary arterial hypertension, Opsumit, got off to a better-than-expected start. Report

> A 6 month experiment in diabetes management, using mobile communications including texts, boosted prescription costs because of better drug adherence, but saved more than $32,000 on doctor visits, ER trips and other services. Report

> Seattle Genetics ($SGEN) promoted two commercial executives--Chris Boerner, to EVP, Commercial; and Charles (Chip) Romp to SVP, Sales--and added David Fontana as VP of portfolio management and Adcetris program manager. Release

> Keryx Biopharmaceuticals brought on Greg Madison as EVP and chief operating officer; he will be charged with building a commercial organization to support the potential launch of Zerenex, a drug for kidney patients. Release

And Finally... Some doctors argue caution in using new obesity drugs from Arena Pharmaceuticals ($ARNA) and Vivus ($VVUS). Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?